Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Meanwhile, Mounjaro – which is approved for diabetes ... but had also not reached a plateau. Lilly is losing no time in advancing retatrutide into phase 3 testing, announcing a large and wide ...

With weight loss drugs such as Ozempic and Mounjaro seemingly able to melt the pounds away, you might well think you'll never need a 'diet plan' again. Alas, you'd be wrong. As a leading weight ...

The shortage, which began in December 2022 for Mounjaro and extended to Zepbound in April 2023, led to a surge in demand for compounded versions of the drugs. But with tirzepatide removed from the ...

Demand for weight loss jabs continues to surge, particularly as the NHS began offering Wegovy in late 2023 and will start offering Mounjaro to patients in March 2025. They have also become ...

Adam Gilden, MD, MSCE, is an associate director of the Obesity Medicine Fellowship at University of Colorado School of Medicine and associate director of the Colorado University Medicine Weight ...

Eli Lilly's main revenue drivers are diabetes drugs and weight loss medication, specifically Mounjaro and Zepbound. It also manufactures antidepressants, most notably Prozac, and it's developing a ...

Manufactured by Eli Lilly and Company, both Mounjaro and Zepbound contain the active ingredient tirzepatide. Tirzepatide is similar to semaglutide, which is used in medications like Ozempic, Rybelsus, ...